Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience
Crossref DOI link: https://doi.org/10.1007/s12032-015-0485-2
Published Online: 2015-01-31
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Petrioli, R.
Roviello, G.
Fiaschi, A. I.
Laera, L.
Miano, Salvatora T.
De Rubertis, G.
Barbanti, G.
Bianco, V.
Brozzetti, S.
Francini, E.
Text and Data Mining valid from 2015-01-31